Stock ANTX AN2 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.015 USD -1.23% Intraday chart for AN2 Therapeutics, Inc. -0.25% -90.17%
May. 16 Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating MT
May. 14 AN2 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating
MT
AN2 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
BU
North American Morning Briefing : Powell Awaited -2-
DJ
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform
MT
North American Morning Briefing : Stocks Seen -2-
DJ
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
BU
AN2 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
AN2 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
PR
North American Morning Briefing :Stock Futures -2-
DJ
Leerink Partners Downgrades AN2 Therapeutics to Market Perform From Outperform, Adjusts PT to $7 From $23
MT
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease
AQ
North American Morning Briefing : Stocks Seen -2-
DJ
US Equity Markets Close Mixed Monday Ahead of Inflation Data for January
MT
Sector Update: Health Care Stocks Mixed Late Afternoon
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANTX Stock
  4. News AN2 Therapeutics, Inc.